Viral interaction with host eIF2alpha kinases
病毒与宿主 eIF2α 激酶的相互作用
基本信息
- 批准号:9789821
- 负责人:
- 金额:$ 60.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-24 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenovirus InfectionsAdenovirusesAffectAmino AcidsAntiviral AgentsAntiviral ResponseBindingBinding SitesBiological AssayBiologyBunyaviridaeCellsCellular StressColorDNA VirusesDataDevelopmentDiseaseDouble-Stranded RNAEnzymesEukaryotic Initiation Factor-2FamilyFamily PicornaviridaeGene ExpressionGoalsGrowthHIV-1Host DefenseHumanIn VitroInfectionInfection ControlKnowledgeLaboratoriesMessenger RNAMissionMolecularMolecular VirologyMurid herpesvirus 1MusNucleic AcidsPathogenesisPhosphorylationPhosphotransferasesProteasome InhibitorProtein AnalysisProtein BiosynthesisRNARNA Polymerase IIIReportingResearchRoleSindbis VirusSystemTestingTimeTranscriptTranslatingTranslationsUbiquitinationUnited States National Institutes of HealthUntranslated RNAViralViral GenesViral PathogenesisViral ProteinsVirusVirus DiseasesVirus Replicationbasecytokinedeprivationdisorder controlexperimental studyhuman diseasein vivoin vivo Modelinnovationmacromoleculemacrophagemortalitymouse modelmulticatalytic endopeptidase complexmutantpreventprotein activationprotein kinase Rresponsevirologyvirus host interaction
项目摘要
Summary
Viruses use many strategies to translate their mRNAs in the face of antiviral responses that would otherwise
block viral protein synthesis. The most prominent antiviral mechanism affecting protein synthesis is
phosphorylation of eukaryotic initation factor 2 (eIF2 by protein kinase R (PKR). Human adenoviruses
(hAds) overcome this via virus-associated (VA) RNAs that block PKR activation. However, mouse adenovirus
type 1 (MAV-1) does not encode VA RNAs; how MAV-1 successfully overcomes PKR is unknown. The role of
another eIF2 kinase, GCN2, in antiviral responses is less well appreciated, but it is antiviral against MAV-1.
There is a critical need to understand how PKR and GCN2 impact viral replication as part of the antiviral
response. The long-term goal is to increase fundamental knowledge about adenovirus-host interactions that
contribute to disease. The overall objective of this application is to determine how MAV-1 modulates host
eIF2 kinases and successfully replicates in the presence of these host antiviral defenses. The central
hypothesis is that MAV-1 overcomes the host antiviral response by reducing PKR levels, whereas MAV-1
activates but does not evade GCN2 in macrophages, target cells of viral replication. This hypothesis is based
on preliminary data that PKR is depleted in MAV-1 infections, GCN2-deficient macrophages produce more
virus, and GCN2-deficient mice are more susceptible and express more proinflammatory cytokines upon
MAV-1 infection than control mice. The rationale is that knowing how MAV-1 induces and counteracts the host
antiviral responses will enable manipulation of these responses and testing their effects in a powerful in vivo
model, which will increase understanding of disease. The specific aims are to determine 1) how MAV-1
counters the host PKR response, and 2) how the host GCN2 response protects mice from MAV-1 infection.
These aims will use assays of MAV-1 pathogenesis and molecular virology established in the applicant's
laboratory. In Aim 1, preliminary data showing that during infection PKR is degraded via the proteasome and
PKR translation is inhibited will be validated and extended to identify the mechanisms and whether specific
viral genes are responsible. Approaches will use viral mutants, PKR-/- mice and cells. Aim 2 will address how
the lack of GCN2 leads to higher mouse mortality and proinflammatory responses, and whether and how
MAV-1 induces GCN2 activation, using viral mutants, and wild type and GCN2-/- mice and cells. The approach
is innovative because it will elucidate for the first time how a DNA virus induces depletion of PKR, and it will
broaden the focus on eIF2 kinase GCN2 as a host antiviral response. The research is significant because it is
expected to have fundamental relevance to virus-host interactions and human disease.
总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Katherine R. Spindler其他文献
Katherine R. Spindler的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Katherine R. Spindler', 18)}}的其他基金
Viral interaction with host eIF2alpha kinases
病毒与宿主 eIF2α 激酶的相互作用
- 批准号:
9976443 - 财政年份:2018
- 资助金额:
$ 60.82万 - 项目类别:
Viral interaction with host eIF2alpha kinases
病毒与宿主 eIF2α 激酶的相互作用
- 批准号:
10459361 - 财政年份:2018
- 资助金额:
$ 60.82万 - 项目类别:
American Society for Virology Meeting - Jr. Investigator Support Proposal
美国病毒学学会会议 - 初级研究员支持提案
- 批准号:
9932318 - 财政年份:2011
- 资助金额:
$ 60.82万 - 项目类别:
Mechanisms of blood-brain barrier disruption by an encephalitic virus
脑炎病毒破坏血脑屏障的机制
- 批准号:
8651867 - 财政年份:2011
- 资助金额:
$ 60.82万 - 项目类别:
American Society for Virology Meeting- Jr Investigator Support
美国病毒学学会会议 - 初级研究者支持
- 批准号:
10623137 - 财政年份:2011
- 资助金额:
$ 60.82万 - 项目类别:
Mechanisms of blood-brain barrier disruption by an encephalitic virus
脑炎病毒破坏血脑屏障的机制
- 批准号:
8183521 - 财政年份:2011
- 资助金额:
$ 60.82万 - 项目类别:
Mechanisms of blood-brain barrier disruption by an encephalitic virus
脑炎病毒破坏血脑屏障的机制
- 批准号:
8449166 - 财政年份:2011
- 资助金额:
$ 60.82万 - 项目类别:
Mechanisms of blood-brain barrier disruption by an encephalitic virus
脑炎病毒破坏血脑屏障的机制
- 批准号:
8260848 - 财政年份:2011
- 资助金额:
$ 60.82万 - 项目类别:
Cloning a major gene for mouse adenovirus susceptibility
克隆小鼠腺病毒易感性主要基因
- 批准号:
7846601 - 财政年份:2009
- 资助金额:
$ 60.82万 - 项目类别:
Cloning a major gene for mouse adenovirus susceptibility
克隆小鼠腺病毒易感性主要基因
- 批准号:
7753149 - 财政年份:2006
- 资助金额:
$ 60.82万 - 项目类别:
相似海外基金
RNA interference based therapies for treatment of adenovirus infections in immunosuppressed host
基于 RNA 干扰的疗法用于治疗免疫抑制宿主的腺病毒感染
- 批准号:
211658021 - 财政年份:2012
- 资助金额:
$ 60.82万 - 项目类别:
Research Grants
ASSESSING THE PREVALENCE OF THE BK, CMV, & ADENOVIRUS INFECTIONS IN PED PTS
评估 BK、CMV 的患病率
- 批准号:
7716731 - 财政年份:2008
- 资助金额:
$ 60.82万 - 项目类别:
ASSESSING THE PREVALENCE OF THE BK, CMV, & ADENOVIRUS INFECTIONS IN PED PTS
评估 BK、CMV 的患病率
- 批准号:
7982151 - 财政年份:2008
- 资助金额:
$ 60.82万 - 项目类别:
ASSESSING THE PREVALENCE OF THE BK, CMV, & ADENOVIRUS INFECTIONS IN PED PTS
评估 BK、CMV 的患病率
- 批准号:
7603956 - 财政年份:2006
- 资助金额:
$ 60.82万 - 项目类别:
Immunotherapy of Adenovirus Infections in Stem Cell Transplnt Recipients
干细胞移植受体中腺病毒感染的免疫治疗
- 批准号:
7337161 - 财政年份:2006
- 资助金额:
$ 60.82万 - 项目类别:
Immunotherapy of Adenovirus Infections in Stem Cell Transplant Recipients
干细胞移植受者腺病毒感染的免疫治疗
- 批准号:
7167150 - 财政年份:2006
- 资助金额:
$ 60.82万 - 项目类别:
Immunotherapy of Adenovirus Infections in Stem Cell Transplnt Recipients
干细胞移植受体中腺病毒感染的免疫治疗
- 批准号:
7020895 - 财政年份:2006
- 资助金额:
$ 60.82万 - 项目类别:
Immunotherapy of Adenovirus Infections in Stem Cell Transplnt Recipients
干细胞移植受体中腺病毒感染的免疫治疗
- 批准号:
7545814 - 财政年份:2006
- 资助金额:
$ 60.82万 - 项目类别:
ASSESSING THE PREVALENCE OF THE BK, CMV, & ADENOVIRUS INFECTIONS IN PED PTS
评估 BK、CMV 的患病率
- 批准号:
7368241 - 财政年份:2005
- 资助金额:
$ 60.82万 - 项目类别:
National Surveillance for Emerging Adenovirus Infections
新发腺病毒感染的国家监测
- 批准号:
6899378 - 财政年份:2004
- 资助金额:
$ 60.82万 - 项目类别:














{{item.name}}会员




